ImmunoSYS is mainly interested in research that is immunology focused. More specifically, research areas where the ‘Danger Model’ of immunology can be applied or tested receive our attention and effort. This could be in a variety of areas such as:

We also engage in research with our clients in projects that are spin-offs of business. These may offer the scope to study the (i) biological aspects, or (ii) business model and commercial aspects, of a biological business.




Comprehensive human in vitro immune testing (COMPIT) is the major research undertaking of ImmunoSYS in partnership with Abundnz BV (Netherlands based CRO). This project is focused on developing a state-of-the-art preclinical human testing platform for drug molecules.


Immuno-regulatory Cytokine

The development of a stable IL-10 and variants as a research grade cytokine for anti-inflammation and immune modulation studies. 
ImmunoSYS is preparing to apply for UK/EU grants for this project in collaboration with partners in the UK and the EU. The stable IL-10 is an engineered cytokine designed to be a therapeutic that is in a concept stage currently. We are partners for the technical and commercial development of the product.



The isolation and characterisation of probiotic strains endemic to the South Asian region including Bangladesh. ImmunoSYS will be initiating this project in 2016 in collaboration with industrial (Phenix Biologics and Biosystems) and academic partners in Bangladesh.




ImmunoSYS stems from a strong a research background and intends to form research collaborations with research groups who are looking for UK partnerships. Our interests are in life sciences that fall within major therapeutic areas such as immunology, inflammation, cardiovascular biology, diabetes, endocrine problems, autoimmunity, cell matrix and tissues, wound healing and cancer studies. We will join as an R&D SME in collaborative research and will facilitate partnership with UK academic research groups. We are particularly interested in research collaborations under the Horizon 2020 and similar British or EU grant schemes.